期刊
INTERNATIONAL JOURNAL OF CARDIOLOGY
卷 252, 期 -, 页码 80-87出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2017.10.086
关键词
Muir congenital heart disease; Heart failure; B-type nattiuretic peptide; Transplant; Ventricular assist device
资金
- Frans van de Werf Fund for Clinical Cardiovascular Research
- Nevil Thomas Fellowship in Adult Congenital Heart Disease
- Research Foundation Flanders (FWO)
Objective: Although heart failure (HF) is the leading cause of premature death in adult congenital heart disease (ACHD), little population-specific data exist. This study reports early experience from a dedicated, subspecialty adult congenital heart disease-heart failure (ACHD-HF) clinic, aiming to identify risk factors for adverse outcome. Methods: Between 2012 and 2015, 126 patients (57% male) attended the ACHD-HF dinic. Baseline and follow-up data were analysed and compared across 4 anatomical/physiological subgroups: cyanotic ACHD, Fontan circulation ( IV), biventricular circulation with a subaortic right ventricle (2V-RV) and biventricular circulation with a subaortic left ventricle (2V-LV). Predictors of the composite primary outcome: death, transplant or ventricular assist device (VAD) were identified using multivariable Cox proportional hazard models. Results: Mean age at first visit was 38 +/- 13 years. Patients were grouped as follows: cyanotic ACHD 10%, 1 V 24%, 2V-RV 29% and 2V-LV 37%. During a median follow-up of 1.7 (IQR 0.8-2.9) years, 38 patients (30%) reached the primary outcome. Event-free survival was 89%, 78% and 63% at 1, 2 and 3 years. Forty (31.7%) patients experienced 69 HF hospitalisations. Between-group differences were noted for systolic function, valvular regurgitation, pacing prevalence and invasive hemodynamics. Multivariable analysis revealed 2V-RV subgroup (p = 0.001), NYHA class (p 0.002) B-type natriuretic peptide >164 pg/ml (p = 0.003) and sodium <136 mmol/L (p 0.036) as independently associated with death, transplant or VAD. Conclusions: Our young ACHD-HF patients experienced high adverse event rates during a short period of followup. The prognostic markers identified will aid clinicians to stratify short-term risk and thereby guide advanced HF management decisions in ACHD. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据